NRG-GY025 Endometrial Cancer

We are doing this study to find out if the study drugs nivolumab and ipilimumab are a safe and effective option for people who have endometrial cancer that does not respond to standard treatment and/or has spread to other parts of the body. We want to compare the results of using these 2 drugs together versus using nivolumab alone.

Recurrent or Metastatic Endometrial Cancer

Women ages 18+ who:

• Are diagnosed with recurrent or metastatic endometrial cancer
• Have not received more than 2 previous lines of therapy

For more information about who can join this study, contact the study team at nick.jeffries@duke.edu.

If you decide to participate in this study, you will get a random assignment (like a coin flip) to 1 of 2 groups:

• Group 1: You will get the study drugs nivolumab and ipilimumab. You will get the nivolumab through a vein in the arm or through a port on the first day of each cycle. Each cycle lasts 3 weeks. You will also get the drug ipilimumab through a vein in the arm or through a port on the first day of every other cycle (every 6 weeks).

• Group 2: You will receive the study drug nivolumab. You will get this drug through a vein in the arm or through a port on the first day of each cycle.